Shalini Shah

ORCID: 0000-0001-5200-225X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pain Management and Opioid Use
  • Opioid Use Disorder Treatment
  • Musculoskeletal pain and rehabilitation
  • Anesthesia and Pain Management
  • Cannabis and Cannabinoid Research
  • Migraine and Headache Studies
  • Botulinum Toxin and Related Neurological Disorders
  • Pain Management and Treatment
  • Cardiovascular Syncope and Autonomic Disorders
  • Innovations in Medical Education
  • Pediatric Pain Management Techniques
  • Pain Management and Placebo Effect
  • Spine and Intervertebral Disc Pathology
  • Pain Mechanisms and Treatments
  • Cancer Treatment and Pharmacology
  • Southeast Asian Sociopolitical Studies
  • Cardiac, Anesthesia and Surgical Outcomes
  • Ophthalmology and Eye Disorders
  • COVID-19 and healthcare impacts
  • Shoulder Injury and Treatment
  • Pharmaceutical Practices and Patient Outcomes
  • Cardiac Arrest and Resuscitation
  • Telemedicine and Telehealth Implementation
  • Long-Term Effects of COVID-19
  • Intramuscular injections and effects

University of California, Irvine
2015-2025

Miami Dermatology and Laser Institute
2025

University of Miami
2025

UC Irvine Health
2021-2023

Riverside Community Hospital
2022

University of Virginia
2020

Albert Einstein College of Medicine
2020

Pain and Rehabilitation Medicine
2010

Tri-Institutional PhD Program in Chemical Biology
2010

Cornell University
2010

Background: The unexpected COVID-19 crisis has disrupted medical education and patient care in unprecedented ways. Despite the challenges, health-care system patients have been both creative resilient finding robust “temporary” solutions to these challenges. It is not clear if some of COVID-era transitional steps will be preserved future telemedicine. Objectives: goal this commentary address sometimes substantial changes education, continuing (CME) activities, residency fellowship programs,...

10.36076/ppj.2020/23/s367 article EN Pain Physician 2020-08-14

The past two decades have seen an increase in cannabis use due to both regulatory changes and interest potential therapeutic effects of the substance, yet many aspects substance their health implications remain controversial or unclear.In November 2020, American Society Regional Anesthesia Pain Medicine charged Cannabis Working Group develop guidelines for perioperative cannabis. Perioperative Use Cannabinoids Guidelines Committee was with drafting responses nine key questions using a...

10.1136/rapm-2022-104013 article EN cc-by-nc-sa Regional Anesthesia & Pain Medicine 2023-01-03

The US Health and Human Services Pain Management Best Practices Inter-Agency Task Force initiated a public–private partnership which led to the publication of its report in 2019. emphasized need for individualized, multimodal, multidisciplinary approaches pain management that decrease over-reliance on opioids, increase access care, promote widespread education substance use disorders. specifically called specialty organizations work together develop evidence-based guidelines. In response...

10.1136/rapm-2021-103083 article EN Regional Anesthesia & Pain Medicine 2021-09-22

Introduction The purpose of this study is to determine baseline demographics and utilization trend an on-demand, synchronous tele-ophthalmology triage program in evaluating acute ophthalmic concerns during the COVID-19 Public Health Emergency. Methods Setting: Single-center retrospective chart review telemedicine visits conducted by ophthalmologists optometrists from University Miami’s Bascom Palmer Eye Institute. Patient population: 6227 patients comprised 7138 telehealth encounters. All...

10.3389/fopht.2024.1511378 article EN cc-by Frontiers in Ophthalmology 2025-01-14

Background Intra-articular corticosteroid (IACS) injection and peri-articular are commonly used to treat musculoskeletal conditions. Results vary by region, but most studies report short-term benefit with mixed results on long-term relief. Publications showed adverse events from single injections. Recommended effective doses were lower than those currently clinicians. Methods Development of the practice guideline for joint injections was approved Board Directors American Society Regional...

10.1136/rapm-2024-105656 article EN other-oa Regional Anesthesia & Pain Medicine 2025-02-26

Significant knowledge gaps exist in the perioperative pain management of patients with a history chronic pain, substance use disorder, and/or opioid tolerance as highlighted US Health and Human Services Pain Management Best Practices Inter-Agency Task Force 2019 report. The report emphasized challenges caring for these populations need multidisciplinary care comprehensive approach. Such requires stakeholder alignment across multiple specialties settings. With intention codifying this into...

10.1136/rapm-2023-104435 article EN Regional Anesthesia & Pain Medicine 2023-04-25

BACKGROUND: Opioid prescribing in the United States is decreasing, however, opioid epidemic continuing at an uncontrollable rate. Available data show a significant number of deaths, primarily associated with illicit fentanyl use. It interesting to also note that no clear correlation between (either prescriptions or morphine milligram equivalent [MME] per capita), hospitalizations, and deaths. Furthermore, suggest 2016 guidelines from Centers for Disease Control Prevention (CDC) have resulted...

10.36076/ppj.2023.26.s7 article EN Pain Physician 2023-12-20

The synthetic opioid methadone is a promising analgesic for the management of chronic neuropathic pain. Methadone therapy increasing as its advantages are being realized over other opioids. Methadone's lack known active metabolites, high oral bioavailability, low cost, and additional receptor activity an antagonist N-methyl-D-aspartate receptors make it attractive analgesic.We surveyed 550 pain physicians to determine their prescribing practices methadone. study was approved by our...

10.36076/ppj.2010/13/289 article EN Pain Physician 2010-05-14

Introduction OnabotulinumtoxinA (OBTA) is approved for treating chronic headaches and migraines in adults, but there limited scientific literature on the outcomes pediatric patients. The aim of this study was to determine if subjects treated with OBTA reported a statistically significant improvement primary features (frequency, intensity, duration disability scoring) associated compared placebo at follow-up visits. Methods After obtaining approval by appropriate local (HS# 2016–3108) federal...

10.1136/rapm-2020-101605 article EN Regional Anesthesia & Pain Medicine 2020-10-26

Background: The use of onabotulinumtoxin A in the pediatric population has not been evaluated for chronic migraine a longitudinal study. This retrospective study sought to determine efficacy and safety prophylactic treatment population. Methods: authors retrospectively patients who had treated with outpatient pain clinic migraine. Demographic data pre- posttreatment days (frequency), scores (intensity), duration episodes were collected from patient records. Results: Ten included. Median...

10.1177/0883073818776142 article EN Journal of Child Neurology 2018-06-07

The past two decades have seen an exponential increase in the use of cannabis and cannabinoids USA, as a result both regulatory changes public interest possible therapeutic benefits. Patients presenting for surgery are using with increasing frequency

10.1136/rapm-2022-104193 article EN Regional Anesthesia & Pain Medicine 2023-01-03

Background: Chronic pain patients require continuity of care even during the COVID-19 pandemic, which has drastically changed healthcare and other societal practices. The American Society Interventional Pain Physicians (ASIPP) created COVID-ASIPP Risk Mitigation Stratification (COVID-ARMS) Return to Practice Task Force in order provide guidance for safe strategic reopening. Objectives: aims are education interventional specialists their pandemic that minimizes COVID-related morbidity while...

10.36076/ppj.2020/23/s161 article EN Pain Physician 2020-08-14

Study Design. A retrospective cohort study of utilization patterns and variables epidural injections in the fee-for-service (FFS) Medicare population. Objectives. To update managing chronic pain FFS population, from 2000 to 2020, assess impact COVID-19. Summary Background Data. The analysis interventional techniques also showed an annual decrease 2.5% per 100,000 enrollees 2009 2018 contrasting increase 7.3% 2009. COVID-19 pandemic has not been assessed. Methods. This was performed by...

10.1097/brs.0000000000004574 article EN Spine 2022-12-28

The University of California (UC) leadership sought to develop a robust educational response the epidemic opioid-related deaths. Because contributors this current crisis are multifactorial, comprehensive requires educating future physicians about safe and effective management pain, safer opioid prescribing, identification treatment substance use disorder (SUD).The six UC medical schools appointed an workgroup strategies coordinated epidemic. had diverse specialty disciplinary representation....

10.1093/pm/pnaa399 article EN Pain Medicine 2020-11-10

The opioid epidemic was triggered by an overprescription of analgesics. In the treatment chronic pain, repeated administrations are required which ultimately lead to tolerance, physical dependence, and addiction. A possible way overcome this conundrum consists a co-medication that maintains analgesic benefits opioids while preventing their adverse liabilities. YHS, extract plant Corydalis yanhusuo, has been used as in traditional Chinese medicine for centuries. More recently, it shown...

10.3390/ph14101034 article EN cc-by Pharmaceuticals 2021-10-12

See Article, pages 5, 16, 31, 42, 54 The global use of cannabinoids for both recreational and medicinal purposes is accelerating at a remarkable pace. In the United States, cannabis has seemingly achieved stature as therapeutic ailments from cancer to pain without scientific rigor or regulatory oversight required other traditional therapeutics. By 2030, cannabinoid market capitalization predicted be approximately US $100 billion, which will far surpass that largest pharmaceutical company in...

10.1213/ane.0000000000006592 article EN Anesthesia & Analgesia 2023-12-15
Coming Soon ...